Jan 2019

Jan 17, 2019 Shareholder Update January 2019

Jan 02, 2019 VivaGel® condom receives final regulatory approval in Japan

Dec 2018

Dec 27, 2018 US FDA requests further data for VivaGel® BV approval

Dec 20, 2018 US VivaGel® BV licensed for A$142M milestones, plus royalties

Dec 12, 2018 US patent granted for SPL7013 eye drops for conjunctivitis

Nov 2018

Nov 29, 2018 AGM - Chairman address and CEO presentation

Nov 16, 2018 DEP® docetaxel and DEP® cabazitaxel outperform in human pancreatic cancer model

Oct 2018

Oct 26, 2018 Quarterly Cashflow Report

Oct 17, 2018 Starpharma Investor Presentation for Citi Conference

Sep 2018

Sep 05, 2018 DEP® irinotecan outperforms in pancreatic cancer model

Aug 2018

Aug 31, 2018 AstraZeneca’s DEP Bcl2/xL inhibitors show compelling efficacy and synergy in combination

Aug 22, 2018 Motley Fool ‘Extreme Opportunities’ Advisor Dr Anirban Mahanti covers Starpharma’s 2018 Financial Year Results

Aug 21, 2018 Annual report and full year financial results

Jul 2018

Jul 17, 2018 Quarterly Cashflow Report

Jul 16, 2018 Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler for The Constant Investor

Jul 09, 2018 VivaGel® BV NDA advances to next stage of FDA review

Jul 01, 2018 Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler on Talking Business

Jul 01, 2018 Starpharma CEO Jackie Fairley featured on Qantas’ inflight magazine Travel Insider

Jun 2018

Jun 27, 2018 Starpharma licenses VivaGel® BV to Mundipharma for Europe

May 2018

May 03, 2018 Mundipharma licenses Starpharma’s VivaGel® BV

Apr 2018

Apr 30, 2018 Quarterly Cashflow Report

Apr 30, 2018 Starpharma completes US New Drug Application for VivaGel® BV

Apr 30, 2018 VivaGel® BV - Product Information and Independent Market Research

Apr 11, 2018 Starpharma to present at OTCQX Virtual Investor Conference

Mar 2018

Mar 14, 2018 Starpharma on CommSec’s The Executive Series

Mar 08, 2018 Starpharma CEO Dr Jackie Fairley on Channel 9’s The Today Show for International Women’s Day

Feb 2018

Feb 26, 2018 Starpharma Interim Report and Half-Year Financial Results

Feb 22, 2018 Starpharma receives $3.7M R&D tax incentive refund

Feb 19, 2018 Shareholder Update February 2018

Jan 2018

Jan 31, 2018 Starpharma announces DEP cabazitaxel Phase 1/2 Trial

Jan 31, 2018 Starpharma to commence DEP® cabazitaxel phase 1/2 trial

Jan 25, 2018 Appendix 4C - Quarterly Cashflow Report

Jan 23, 2018 AstraZeneca plans to make better use of Australia’s innovation

Dec 2017

Dec 21, 2017 VivaGel® BV treatment clinical submission under rolling submission

Nov 2017

Nov 29, 2017 AGM Chairman’s address and CEO presentation

Nov 21, 2017 NDA submission for Starpharma’s VivaGel® BV

Nov 21, 2017 NDA submission for VivaGel® BV in the US

Oct 2017

Oct 27, 2017 Notice of Annual General Meeting/Proxy Form

Oct 26, 2017 Appendix 4C – Quarterly Cashflow Report

Oct 25, 2017 Starpharma receives TGA marketing approval for VivaGel® BV

Oct 25, 2017 VivaGel® BV granted marketing approval in Australia

Oct 23, 2017 Morgans Under the Microscope Interview featuring Dr Jackie Fairley

Oct 18, 2017 Shareholder Update October 2017

Oct 09, 2017 Starpharma and Peter Mac Cancer Centre awarded DEP® Grant

Sep 2017

Sep 28, 2017 AstraZeneca presents first DEP® candidate as Bcl2/xL inhibitor

Sep 26, 2017 Starpharma reports positive phase 1 results

Sep 23, 2017 Starpharma rockets on cancer drug hope

Sep 22, 2017 DEP® docetaxel positive phase 1 results; phase 2 commences

Aug 2017

Aug 28, 2017 Starpharma featured on Sky Business News

Aug 28, 2017 Starpharma annual report and full year financial results